Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

 Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

Shots:

  • Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B
  • The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of outstanding QIAGEN shares at the end acceptance period on Aug 10, 2020, with $95M reimbursement to Thermo Fisher, if the minimum acceptance threshold is not met
  • QIAGEN’s Supervisory and Managing Boards reaffirm unanimous recommendation that all shareholders accept and tender all their QIAGEN shares in the offer prior to the end of the acceptance period. The transaction is expected to be completed in H1’21

Click here to read full press release/ article | Ref: PRNewswire | Image: MPO

Related News: Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post